Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Non-Current Deferred Tax Liability (2024 - 2025)

PharmaCyte Biotech (PMCB) has disclosed Non-Current Deferred Tax Liability for 2 consecutive years, with $140985.0 as the latest value for Q2 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 86.47% to $140985.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $140985.0 through Apr 2025, down 86.47% year-over-year, with the annual reading at $140985.0 for FY2025, 86.47% down from the prior year.
  • Non-Current Deferred Tax Liability for Q2 2025 was $140985.0 at PharmaCyte Biotech, down from $1.0 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $1.0 million in Q2 2024, with the low at $140985.0 in Q2 2025.